Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.32 |
| ▸ | CA12 | O43570 | 2/20 | 0.32 |
| ▸ | GMNN | O75496 | 2/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | CA1 | P00915 | 2/20 | 0.32 |
| ▸ | CA2 | P00918 | 2/20 | 0.32 |
| ▸ | LMNA | P02545 | 2/20 | 0.32 |
| ▸ | BLM | P54132 | 2/20 | 0.32 |
| ▸ | CA9 | Q16790 | 2/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.32 |
| ▸ | SGMS1 | Q86VZ5 | 1/20 | 0.32 |
| ▸ | SGMS2 | Q8NHU3 | 1/20 | 0.32 |
| ▸ | CTDSP1 | Q9GZU7 | 2/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9276620 | 1.00 | MAPT (0.32) | MAPTCA12GMNNALDH1A1CA1 | |
| SCHEMBL18434998 | 1.00 | MAPT (0.32) | MAPTCA12GMNNALDH1A1CA1 | |
| SCHEMBL28257150 | 0.91 | MAPT (0.32) | MAPTCA12GMNNALDH1A1CA1 | |
| SCHEMBL17538638 | 0.91 | MAPT (0.32) | MAPTCA12GMNNALDH1A1CA1 | |
| SCHEMBL25688662 | 0.91 | MAPT (0.32) | MAPTCA12GMNNALDH1A1CA1 | |
| SCHEMBL18683565 | 0.91 | MAPT (0.32) | MAPTCA12GMNNALDH1A1CA1 | |
| SCHEMBL11283293 | 0.91 | MAPT (0.32) | MAPTCA12GMNNALDH1A1CA1 | |
| SCHEMBL4544647 | 0.91 | MAPT (0.32) | MAPTCA12GMNNALDH1A1CA1 | |
| SCHEMBL18391716 | 0.91 | MAPT (0.32) | MAPTCA12GMNNALDH1A1CA1 | |
| SCHEMBL18683555 | 0.91 | MAPT (0.32) | MAPTCA12GMNNALDH1A1CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200030304-A1 | MITIGATION OF CNS DISORDERS BY COMBINATION THERAPY USING NEUROSTEROIDS, AND AMPA BLOCKERS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2020-01-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200030304-A1 | MITIGATION OF CNS DISORDERS BY COMBINATION THERAPY USING NEUROSTEROIDS, AND AMPA BLOCKERS | GABRA4, GABRG1, GABRB2 | MAPT 1740/4885CA12 2289/4885GMNN 4497/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.